Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies.

ABSTRACT:

Objective

Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies. However, the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells, thus making some patients ineligible for the procedure.

Methods

We developed a simple method for CAR-T cell preparation requiring small volumes of peripheral blood. First, CD3⁺ T cells isolated from 50 mL peripheral blood from patients (B-cell malignancies) were stimulated with immobilized anti-CD3/RetroNectin in 6-well plates and then transduced with CAR-expressing lentiviral vector. After 4 d, the T cells were transferred to culture bags for large-scale CAR-T cell expansion. In vitro and ani

SUBMITTER: Han L 

PROVIDER: S-EPMC8610157 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature